Drugs / Patient-derived CD22-specific CAR T-cells also expressing an EGFRt
Patient-derived CD22-specific CAR T-cells also expressing an EGFRt
Cell therapy targets CD22 via depletion
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03244306 | Jul 2017 → Nov 2018 | leukemia | Seattle Children's Hospital | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Patient-derived CD22-specific CAR T-cells also expressing an EGFRt | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03244306 ↗ |
| Action | Deplete | “The CAR enables the T-cell to recognize and kill the leukemic cell through the recognition of CD22” NCT03244306 ↗ |
| Modality | Cell therapy | “T-cells obtained directly from the patient, which can be genetically modified to express a chimeric antigen receptor (CAR)” NCT03244306 ↗ |
| Target | CD22 | “use T-cells obtained directly from the patient, which can be genetically modified to express a chimeric antigen receptor (CAR) to CD22” NCT03244306 ↗ |